Structure of a Protective Epitope of Group B Streptococcus Type III Capsular Polysaccharide

Total Page:16

File Type:pdf, Size:1020Kb

Structure of a Protective Epitope of Group B Streptococcus Type III Capsular Polysaccharide Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide Filippo Carbonia, Roberto Adamoa,1, Monica Fabbrinia, Riccardo De Riccoa, Vittorio Cattaneoa, Barbara Brogionia, Daniele Veggia, Vittoria Pintoa, Irene Passalacquaa, Davide Oldrinia, Rino Rappuolia,2, Enrico Malitoa, Immaculada y Ros Margarita,1, and Francesco Bertia,1,2 aGSK Vaccines, 53100 Siena, Italy Contributed by Rino Rappuoli, March 27, 2017 (sent for review February 3, 2017; reviewed by Dennis L. Kasper and Robert J. Woods) Despite substantial progress in the prevention of group B Strepto- GBS is an encapsulated Gram-positive β-hemolytic pathogen coccus (GBS) disease with the introduction of intrapartum antibiotic causing neonatal sepsis and meningitis, particularly in infants born prophylaxis, this pathogen remains a leading cause of neonatal to mothers carrying the bacteria (12). The GBS capsular PS is infection. Capsular polysaccharide conjugate vaccines have been constituted by multiple RUs (from ∼50 up to 300 per polymer) of tested in phase I/II clinical studies, showing promise for further de- four to seven monosaccharides shaped to form a backbone and one velopment. Mapping of epitopes recognized by protective anti- or two side chains. Ten serotypes presenting a unique pattern of bodies is crucial for understanding the mechanism of action of glycosidic linkages have been identified and their primary struc- vaccines and for enabling antigen design. In this study, we report β the structure of the epitope recognized by a monoclonal antibody tures elucidated (13). Three monosaccharides ( -D-glucopyranose, β β β β with opsonophagocytic activity and representative of the protective -D-Glc; -D-galactopyranose, -D-Gal; and -D-N-acetylglucosamine, response against type III GBS polysaccharide. The structure and the β-D-GlcNAc) are present in all of the described serotypes, and atomic-level interactions were determined by saturation transfer sialic acid (α-N-acetyl-neuraminic acid, NeuNAc) is always found difference (STD)-NMR and X-ray crystallography using oligosaccha- at the terminus of one chain (13). Maternal concentrations of IgG rides obtained by synthetic and depolymerization procedures. The directed to the different GBS capsular serotypes inversely corre- GBS PSIII epitope is made by six sugars. Four of them derive from late with the risk of newborn infection (14), suggesting that anti- MICROBIOLOGY two adjacent repeating units of the PSIII backbone and two of them bodies able to cross the placenta can confer serotype-specific – from the branched galactose sialic acid disaccharide contained in infant protection (15). PS conjugates of different serotypes elicit this sequence. The sialic acid residue establishes direct binding in- antibodies that mediate GBS type-specific opsonophagocytic kill- teractions with the functional antibody. The crystal structure pro- – ing (OPK) in functional assays and protection against GBS chal- vides insight into the molecular basis of antibody carbohydrate – interactions and confirms that the conformational epitope is not lenge in neonate mice (16 20). Furthermore, Ia, Ib, II, III, and V required for antigen recognition. Understanding the structural basis monovalent vaccines, as well as a trivalent combination (Ia, Ib, of immune recognition of capsular polysaccharide epitopes can aid and III), have been proven to be safe and immunogenic in in the design of novel glycoconjugate vaccines. Significance group B Streptococcus | capsular polysaccharide | antigen This article describes the characterization of the antigenic de- acterial cell surface carbohydrates are the interface of mul- terminant of the capsular polysaccharide from the clinically Btiple host interactions and have been targeted to develop relevant serotype III of group B Streptococcus (GBS). NMR and highly efficacious glycoconjugate vaccines against severe infec- X-ray crystallography have been applied to elucidate the in- tions caused by Streptococcus pneumoniae, Haemophilus influ- teraction of type III GBS oligosaccharides obtained by synthetic enzae type b, and Neisseria meningitidis (1, 2). Glycoconjugate and depolymerization procedures of the bacterial poly- vaccines against other important pathogens are under clinical or saccharide with a functional monoclonal antibody. A Fab–GBS preclinical development (2). oligosaccharide complex structure has been solved at high The mapping of polysaccharide (PS) epitopes recognized by resolution (2.7 Å). The results demonstrate the existence of a functional antibodies mediating protection from infection is sialic acid-dependent functional epitope of GBS that is fully crucial for understanding the mechanism of action of this type of contained within four consecutive sugars deriving from the vaccine. In many cases, the antigenic determinants of the im- type III GBS polysaccharide backbone and one branched di- munological properties of PS and the structural details of the saccharide present in this sequence. This finding has implica- minimal epitope targeted by specific functional antibodies are tions for the development of vaccines against GBS infection. unknown. Structural biology has been commonly practiced in the last decade for the characterization of protein antigen–antibody Author contributions: R.A., R.R., I.y.R.M., and F.B. designed research; F.C., M.F., R.D.R., V.C., B.B., D.V., V.P., I.P., D.O., and E.M. performed research; F.C., R.A., M.F., R.D.R., R.R., interactions (3). However, it has been less applied to carbohy- E.M., I.y.R.M., and F.B. analyzed data; and F.C., R.A., R.R., E.M., I.y.R.M., and F.B. wrote drate antigens, in part because of the well-known difficulty of the paper. crystallizing carbohydrates. Reviewers: D.L.K., Harvard Medical School; and R.J.W., University of Georgia. Minimal epitopes can be composed of short, defined glycans Conflict of interest statement: All authors are employees of GSK Vaccines (known as comprising 2–3 monosaccharides, as for the β-(1→2) mannans of Novartis Vaccines at the time of the study). the Candida albicans cell wall (4), Vibrio cholerae O1 (5), Shigella Freely available online through the PNAS open access option. flexneri variant Y (6), and Salmonella (7) O-antigens, or a tetra- Data deposition: The crystal structure has been deposited in the Protein Data Bank, www. saccharide, as for the repeating unit (RU) of S. pneumoniae type pdb.org (PDB ID code 5M63) (deposition ID D_1200001992). 14 PS (Pn14) (8, 9), and even six sugar residues, as in the case of 1R.A., I.y.R.M., and F.B. contributed equally to this work. S. flexneri serotype 2a O-antigen (10). In contrast, the type III PS 2To whom correspondence may be addressed. Email: [email protected] or of Streptococcus agalactiae (group B Streptococcus, GBS) has been [email protected]. proposed as a prototype of a unique length-dependent confor- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. mational epitope (11). 1073/pnas.1701885114/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1701885114 PNAS Early Edition | 1of6 Downloaded by guest on September 30, 2021 nonpregnant and pregnant women, and elicited maternal anti- conjugated to human serum albumin (HSA) (38) (Fig. 1A) could bodies were efficiently transferred to neonates (21–23). be partially blocked by preincubation with soluble Pn14 or desia- GBS strains belonging to the serotype III (GBSIII) are epide- lylated PSIII. Pn14 also partially inhibited antibody-mediated miologically the most relevant in neonatal infections (24). Pio- GBSIII OPK (Fig. 1B), confirming functional activity of both neering immunological studies aimed at elucidating type III-specific types of NeuNAc-dependent and -independent rabbit antibodies. antigenic determinants indicated the presence of the terminal Similar results were described previously in the case of human NeuNAc residue as essential for the elicitation of protective an- responses to GBSIII (27). tibodies (25). Subsequent studies revealed that sera from rabbits An IgG1 mAb was selected by hybridoma cell line technology immunized with GBSIII bacteria and from humans vaccinated (NVS-1-19-5), and its activity was ascertained by OPKA (OPK with PSIII conjugates contained two types of anticarbohydrate titer, 1.03 μg/mL). The selected monoclonal was representative of antibodies—that is, a major population recognizing the native PS the typical response to type III PS and had the properties de- but not its incomplete core antigen derivative lacking sialic acid scribed in the literature (33, 34). Complete inhibition by native (corresponding to the S. pneumoniae PS group 14, Pn14), and a PSIII and absence of inhibition by Pn14 in ELISA and OPKA minor variable population reacting with both the native PSIII and experiments (Fig. 1 A and B) confirmed that the epitope recog- the core antigen (26, 27). Remarkably, both types of human PSIII- nized by this mAb was NeuNAc-dependent. A Fab fragment of induced antibodies were shown to mediate GBSIII OPK, whereas mAb NVS-1-19-5 was prepared by papain proteolytic cleavage, antibodies elicited by Pn14 (desialylated PSIII) did not recognize and its high-affinity binding toward the GBS PSIII was measured GBSIII bacteria and therefore did not mediate GBS OPK (27). × −8 13 by SPR (KD estimated with the Fab 4 10 M). Studies using C NMR spectroscopy highlighted ring-linkage The NeuNAc-Gal covalent link in the lateral chain of the PSIII signal displacements in the core versus the native PS, suggesting RU is the most chemically labile glycosidic bond within the PS, and that NeuNAc residues exert a specific control over the conformation complete loss of NeuNAc residues or reduction of their carboxylic of the native PS (26, 28). Molecular dynamics simulations confirmed groups results in PS structures incapable of inducing functional a more flexible and disordered structure for desialylated PSIII and antibodies (25, 26). To investigate the potential of the obtained suggested that native PSIII could form extended helical structures mAb for probing the integrity of the PSIII antigen, we subjected where each turn was made by more than four RUs (29–32).
Recommended publications
  • Evaluation of T-Cell and B-Cell Epitopes and Design of Multivalent Vaccines Against Htlv-1 Diseases
    EVALUATION OF T-CELL AND B-CELL EPITOPES AND DESIGN OF MULTIVALENT VACCINES AGAINST HTLV-1 DISEASES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Roshni Sundaram, M.S. * * * * * The Ohio State University 2003 Dissertation Committee: Approved by Professor Pravin T.P. Kaumaya, Adviser Professor Christopher M. Walker Adviser Professor Neil R. Baker Department of Microbiology Professor Marshall V. Williams ABSTRACT Human T-cell lymphotropic virus type I (HTLV-1) is a C type retrovirus that is the causative agent of an aggressive T-cell malignancy, adult T-cell leukemia/lymphoma (ATLL). The virus is also implicated in a number of inflammatory disorders, the most prominent among them being HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP). HTLV-1, like many viruses that cause chronic infection, has adapted to persist in the face of an active immune response in infected individuals. The viral transactivator Tax is the primary target of the cellular immune response and humoral responses are mainly directed against the envelope protein. Vaccination against HTLV-1 is a feasible option as there is very little genetic and antigenic variability. Vaccination regimes against chronic viruses must be aimed at augmenting the immune response to a level that is sufficient to clear the virus. This requires that the vaccine delivers a potent stimulus to the immune system that closely resembles natural infection to activate both the humoral arm and the cellular arm. It is also clear that multicomponent vaccines may be more beneficial in terms of increasing the breadth of the immune response as well as being applicable in an outbred population.
    [Show full text]
  • "Epitope Mapping: B-Cell Epitopes". In: Encyclopedia of Life Sciences
    Epitope Mapping: B-cell Advanced article Epitopes Article Contents . Introduction GE Morris, Wolfson Centre for Inherited Neuromuscular Disease RJAH Orthopaedic Hospital, . What Is a B-cell Epitope? . Epitope Mapping Methods Oswestry, UK and Keele University, Keele, Staffordshire, UK . Applications Immunoglobulin molecules are folded to present a surface structure complementary to doi: 10.1002/9780470015902.a0002624.pub2 a surface feature on the antigen – the epitope is this feature of the antigen. Epitope mapping is the process of locating the antibody-binding site on the antigen, although the term is also applied more broadly to receptor–ligand interactions unrelated to the immune system. Introduction formed of highly convoluted peptide chains, so that resi- dues that lie close together on the protein surface are often Immunoglobulin molecules are folded in a way that as- far apart in the amino acid sequence (Barlow et al., 1986). sembles sequences from the variable regions of both the Consequently, most epitopes on native, globular proteins heavy and light chains into a surface feature (comprised of are conformation-dependent and they disappear if the up to six complementarity-determining regions (CDRs)) protein is denatured or fragmented. Sometimes, by acci- that is complementary in shape to a surface structure on the dent or design, antibodies are produced against linear antigen. These two surface features, the ‘paratope’ on the (sequential) epitopes that survive denaturation, though antibody and the ‘epitope’ on the antigen, may have a cer- such antibodies usually fail to recognize the native protein. tain amount of flexibility to allow an ‘induced fit’ between The simplest way to find out whether an epitope is confor- them.
    [Show full text]
  • Mapping B-Cell Epitopes for Nonspecific Lipid Transfer Proteins of Legumes Consumed in India and Identification of Critical Resi
    foods Article Mapping B-Cell Epitopes for Nonspecific Lipid Transfer Proteins of Legumes Consumed in India and Identification of Critical Residues Responsible for IgE Binding Ankita Mishra 1,* and Ashok Kumar 1,2,3,4 1 Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India; [email protected] 2 Centre for Environmental Science and Engineering, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India 3 Centre for Nanosciences, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India 4 The Mehta Family Centre for Engineering in Medicine, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India * Correspondence: [email protected] Abstract: Nonspecific lipid transfer proteins (nsLTPs) have been categorized as panallergens and display widespread occurrence across plant-kingdom. Present study, investigated B-cell epitopes for LTPs from chickpea, mung-bean, cowpea, pigeon-pea, and soybean via in silico methods. In-silico predicted regions were evaluated for epitope-conservancy and property-based peptide similarity search by different allergen databases. Additionally, the in-silico predicted regions were compared Citation: Mishra, A.; Kumar, A. with the experimentally validated epitopes of peach-LTP. Sequence-homology studies showed that Mapping B-Cell Epitopes for chickpea and mung-bean LTPs shared significant homology, i.e., >70% and >60%, respectively, with Nonspecific Lipid Transfer Proteins of other LTP allergens from lentil, garden-pea, peanut, etc. Phylogenetic-analysis also showed chickpea Legumes Consumed in India and and mung-bean LTPs to be closely related to allergenic LTPs from lentil and peanut, respectively. Identification of Critical Residues Responsible for IgE Binding. Foods Epitope-conservation analysis showed that two of the predicted B-cell epitopic regions in chickpea 2021, 10, 1269.
    [Show full text]
  • Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
    Antibodies 2015, 4, 170-196; doi:10.3390/antib4030170 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Review Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases Marta Westwood * and Alastair D. G. Lawson Structural Biology, UCB, 216 Bath Road, Slough, SL1 3WE UK; E-Mail: [email protected]. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-1-753-534-655 (ext.7749); Fax: +44-1-753-536-632. Academic Editor: Dimiter S. Dimitrov Received: 13 May 2015 / Accepted: 9 July 2015 / Published: 15 July 2015 Abstract: Assembly of misfolded proteins into fibrillar deposits is a common feature of many neurodegenerative diseases. Developing effective therapies to these complex, and not yet fully understood diseases is currently one of the greatest medical challenges facing society. Slow and initially asymptomatic onset of neurodegenerative disorders requires profound understanding of the processes occurring at early stages of the disease including identification and structural characterisation of initial toxic species underlying neurodegeneration. In this review, we chart the latest progress made towards understanding the multifactorial process leading to amyloid formation and highlight efforts made in the development of therapeutic antibodies for the treatment of amyloid-based disorders. The specificity and selectivity of conformational antibodies make them attractive research probes to differentiate between transient states preceding formation of mature fibrils and enable strategies for potential therapeutic intervention to be considered. Keywords: antibody; amyloids; conformation; prion; Alzheimer’s; Parkinson’s; fibrils, tau; Huntingtin; protein misfolding 1. Introduction Correct protein folding is crucial for maintaining healthy biological functions.
    [Show full text]
  • Inhibition of Allergic Reactivity Through Targeting Fcεri-Bound Ige with Humanized Low-Affinity Antibodies
    Inhibition of Allergic Reactivity through Targeting Fc εRI-Bound IgE with Humanized Low-Affinity Antibodies This information is current as Ke Zhang, Michael Elias, Hong Zhang, Jeffrey Liu, of September 27, 2021. Christopher Kepley, Yun Bai, Dean D. Metcalfe, Zachary Schiller, Yang Wang and Andrew Saxon J Immunol published online 21 October 2019 http://www.jimmunol.org/content/early/2019/10/19/jimmun ol.1900112 Downloaded from Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 21, 2019, doi:10.4049/jimmunol.1900112 The Journal of Immunology Inhibition of Allergic Reactivity through Targeting Fc«RI-Bound IgE with Humanized Low-Affinity Antibodies Ke Zhang,* Michael Elias,† Hong Zhang,* Jeffrey Liu,* Christopher Kepley,† Yun Bai,‡ Dean D. Metcalfe,‡ Zachary Schiller,x Yang Wang,x and Andrew Saxon* Options for effective prevention and treatment of epidemic allergic diseases remain limited, and particularly so for IgE-mediated 26 28 food allergies.
    [Show full text]
  • Ige – the Main Player of Food Allergy
    DDMOD-431; No of Pages 8 Vol. xxx, No. xx 2016 Drug Discovery Today: Disease Models Editors-in-Chief Jan Tornell – AstraZeneca, Sweden DRUG DISCOVERY Andrew McCulloch – University of California, SanDiego, USA TODAY DISEASE MODELS IgE – the main player of food allergy 1 2,3 2 Henrike C.H. Broekman , Thomas Eiwegger , Julia Upton , 4, Katrine L. Bøgh * 1 Department of Dermatology/Allergology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands 2 Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Paediatrics, Hospital for Sick Children, Toronto, Canada 3 Research Institute, Physiology and Experimental Medicine, The University of Toronto, Toronto, Canada 4 National Food Institute, Technical University of Denmark, Søborg, Denmark Food allergy is a growing problem worldwide, presently Section editor: affecting 2–4% of adults and 5–8% of young children. IgE Michelle Epstein – Medical University of Vienna, is a key player in food allergy. Consequently huge Department of Dermatology, DIAID, Experimental Allergy, Waehringer Guertel 18-20, Room 4P9.02, A1090, efforts have been made to develop tests to detect Vienna, Austria. either the presence of IgE molecules, their allergen binding sites or their functionality, in order to provide allergen ingestion [1], and involve one or more of the follow- information regarding the patient’s food allergy. The ing systems; the skin (pruritus, urticaria, or angioedema), the ultimate goal is to develop tools that are capable of gastro-intestinal tract (diarrhea, vomiting, contractions, in- creased bowel movement), the respiratory tract (asthma at- discriminating between asymptomatic sensitization tack, hoarseness, stridor/laryngeal angioedema) or the and a clinically relevant food allergy, and between cardiovascular system (dizziness, drop in blood pressure, loss different allergic phenotypes in an accurate and trust- of consciousness) [2,3].
    [Show full text]
  • Characterization of Conformational B-Cell
    PEPTIDE-BASED B-CELL EPITOPE VACCINES TARGETING HER-2/NEU DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By Joan T. Garrett, B.S./B.A. ***** The Ohio State University 2007 Dissertation Committee: Approved by Professor Pravin Kaumaya, Advisor ___________________________ Advisor Professor Dehua Pei, Advisor Professor Ross Dalbey ___________________________ Advisor Professor Thomas Magliery Graduate Program in Chemistry ABSTRACT HER-2/neu (ErbB2), a member of the epidermal growth factor family of receptors (EGFR) is overexpressed in a significant fraction of breast cancers. It is an attractive target for receptor-directed antitumor therapy using monoclonal antibodies. Trastuzumab and pertuzumab are growth-inhibitory humanized antibodies targeting the oncogenic protein HER-2/neu. Although passive immunotherapy with trastuzumab is approved for treatment of breast cancer, a number of concerns exist with passive immunotherapy. Treatment is expensive, and has a limited duration of action, necessitating repeated administrations of the monoclonal antibody. Active immunotherapy with conformational B-cell epitopes affords the possibility of generating an enduring immune response, eliciting protein-reactive high-affinity anti-peptide antibodies. The three-dimensional structure of human HER-2 in complex with trastuzumab reveals that the antigen binding region of HER-2 spans residues 563-626 that comprises an extensive disulfide bonding pattern. In order to minimally dissect the interacting binding region of HER-2, we have designed four synthetic peptides with different levels of conformational flexibility. Chimeric peptides incorporating the measles virus fusion ‘promiscuous’ T cell epitope via a four-residue linker sequence were synthesized, purified, and characterized.
    [Show full text]
  • Protein Epitope Mapping by Mass Spectrometry
    Anal. Chem. 1994,66, 3723-3726 Protein Epitope Mapping By Mass Spectrometry Ylngmlng Zhao and Brian T. Chalt’ The Rockefeller University, 1230 York Avenue, New York, New York 10021 A mass spectrometricmethod is described for the rapid mapping antigen bound to an antibody. Alternatively, these workers of linear epitopes in proteins that are bound by monoclonal subjected the peptide to proteolytic digestion and identified antibodies. The method consists of three steps. In the first products that bound to the immobilized antibody. In both step, an antigen protein is digested by a proteolytic enzyme to cases, the peptides of interest were identified by 2Wfplasma produce an appropriate set of peptide fragments. In the second desorption mass spectrometry. step, peptide fragments containing the linear epitope are selected Matrix-assisted laser desorption mass spectrometry (MAL- and separated from the pool of peptide fragments by immu- DI-MS) is a recently developed method for measuring the noprecipitation with the monoclonal antibody. In the final molecular weights of peptides and proteins.12-14 The technique step, the immunoprecipitated peptides are identified by matrix- allows the accurate (better than O.l%), rapid (<1 min), and assisted laser desorption mass spectrometry. The method sensitive (<1 pmol) determination of the molecular weights allows the rapid determination of antigenic sites without tedious of components of complex mixtures of peptides. MALDI- peptide synthesis or protein mutagenesis. The approach is MS is finding wide use for the rapid identification of proteins demonstrated through the mapping of epitopes in two peptides and the elucidation of their primary structures (in particular, (melittin and glucagon-like peptide-1 7-37) against which the definition of posttranslational modifications.) monoclonal antibodies were raised.
    [Show full text]
  • ENCODE DCC Antibody Validation Document
    ENCODE DCC Antibody Validation Document Date of Submission Name: Email: Lab Antibody Name: Target: Company/ Source: Catalog Number, database ID, laboratory Lot Number Antibody Description: Target Description: Species Target Species Host Validation Method #1 Validation Method #2 Purification Polyclonal/ Method Monoclonal Vendor URL: Reference (PI/ Publication Information) Please complete the following for antibodies to histone modifications: if your specifications are not listed in the drop-down box, please write-in the appropriate information Histone Name AA modified AA Position Modification Validation #1 Analysis Insert Validation Image (click here) ARID3A (NB100-279) & (sc-8821) Immunoblot / Immunoprecipitation A. MW (kD) B. MW (kD) C. MW (kD) D. MW (kD) 150 150 150 150 100 100 100 100 75 75 75 75 50 50 50 50 38 38 38 38 25 25 25 20 20 20 25 15 15 15 15 Lane : 1 2 3 4 Lane : 1 2 3 Lane : 1 2 Lane : 1 2 3 A. Western Blot using NB100-279 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2), HeLaS3 (Lane3), and HepG2 (Lane4). B. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody NB100-279. Lane1: Nuclear lysate. Lane 3: Bound material from control immunoprecipitation with rabbit IgG. Lane 2: Bound material from immunoprecipitation with NB100-279. C. Western Blot using sc-8821 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2). D. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody sc-8821 and immunoblot with NB100-279. Lane1: Nuclear lysate. Lane 2: Bound material from immunoprecipitation with sc-8821. Lane 3: Bound material from control immunoprecipitation with Goat IgG.
    [Show full text]
  • Epitope Mapping of an Uncertain Endogenous Antigen Implies Secretogranin II Peptide Splicing [Version 2; Peer Review: 1 Approved, 2 Approved with Reservations]
    F1000Research 2019, 8:1732 Last updated: 26 JUL 2021 RESEARCH ARTICLE Epitope mapping of an uncertain endogenous antigen implies secretogranin II peptide splicing [version 2; peer review: 1 approved, 2 approved with reservations] David R. Howlett 1, Iain J. Clarke2, Russell P. Newton3, John E. Hart4 1Wolfson Centre for Age Related Disease, Kings College London, London, SE1 1UL, UK 2School of Agriculture and Veterinary Science, Melbourne University, Parkville, Victoria, VIC 3010, Australia 3Biochemistry Group, Institute of Life Sciences, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK 4Endocrine Pharmaceuticals Ltd, Tadley, Hampshire, RG26 3TA, UK v2 First published: 09 Oct 2019, 8:1732 Open Peer Review https://doi.org/10.12688/f1000research.20633.1 Latest published: 05 Dec 2019, 8:1732 https://doi.org/10.12688/f1000research.20633.2 Reviewer Status Invited Reviewers Abstract Background: The search for a tissue-mass reducing reproductive 1 2 3 hormone involved a bioassay-guided physicochemical fractionation of sheep blood plasma. This brought forth a candidate protein whose version 2 apparent mass on gels and in mass spectrometry (MS) was 7-8 kDa, (revision) report report implying a polypeptide of ~70 residues. Four purification runs gave 05 Dec 2019 Edman N-terminal sequences relating to 1MKPLTGKVKEFNNI14. This is bioinformatically obscure and has been resistant to molecular version 1 biological investigation. The sequence was synthesized as the peptide 09 Oct 2019 report report EPL001, against which was raised a goat polyclonal antiserum, G530. Used in an antigen capture campaign, G530 pointed to the existence of a novel derivative of secretogranin II (SgII), the neuroendocrine 1.
    [Show full text]
  • Highly Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20136002; this version posted June 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Highly Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping Paul Kearney1, Robert Getts1, Clive Hayward1, David Luta1, Alex Porter1, Marc Witmer1, George du Toit2, Gideon Lack2, R. Sharon Chinthrajah3, Stephen J Galli3,4, Kari Nadeau3, Galina Grishina5, Mayte Suárez-Fariñas5, Maria Suprun5, Hugh A Sampson5 1. AllerGenis LLC, Hatfield, PA, USA 2. King’s College London, London, UK 3. Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, USA 4. Departments of Pathology and Microbiology & Immunology, Stanford University. 5. Department of Pediatrics, Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract Background: Misdiagnosis of peanut allergy is a significant clinical challenge. Here, a novel diagnostic blood-based test using a Bead-Based Epitope Assay (“peanut BBEA”) has been developed on the LEAP cohort and then independently validated on the CoFAR2 and POISED cohorts. Methods: Development of the peanut BBEA followed the National Academy of Medicine’s established guidelines with discovery performed on 133 subjects from the non- interventional arm of the LEAP trial and an independent validation performed on 81 subjects from the CoFAR2 study and 84 subjects from the POISED study. All subject samples were analyzed using the BBEA methodology.
    [Show full text]
  • HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1
    antibodies Article HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1 Marius Gramlich 1, Henry C. W. Hays 2, Scott Crichton 2, Philipp D. Kaiser 1, Anne Heine 1, Nicole Schneiderhan-Marra 1, Ulrich Rothbauer 1,3, Dieter Stoll 1,4, Sandra Maier 1 and Anne Zeck 1,* 1 NMI, Natural and Medical Sciences Institute at the University of Tuebingen, Markwiesenstr. 55, 72770 Reutlingen, Germany; [email protected] (M.G.); [email protected] (P.D.K.); [email protected] (A.H.); [email protected] (N.S.-M.); [email protected] (U.R.); [email protected] (D.S.); [email protected] (S.M.) 2 Medannex Ltd., 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA, UK; [email protected] (H.C.W.H.); [email protected] (S.C.) 3 Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, Geschwister-Scholl-Platz, 72074 Tuebingen, Germany 4 Department of Life Sciences, University of Applied Sciences Albstadt-Sigmaringen, Anton-Guentherstr. 51, 72488 Sigmaringen, Germany * Correspondence: [email protected]; Tel.: +49-7121-51530-0; Fax: +49-7121-51530-816 Abstract: Annexin-A1 (ANXA1) belongs to a class of highly homologous Ca2+-dependent phospholipid- binding proteins. Its structure consists of a core region composed of four homologous repeats ar- ranged in a compact, hydrolysis-resistant structure and an N-terminal region with a Ca2+-dependent conformation. ANXA1 is involved in several processes, including cell proliferation, apoptosis, Citation: Gramlich, M.; Hays, metastasis, and the inflammatory response. Therefore, the development of antibodies blocking H.C.W.; Crichton, S.; Kaiser, P.D.; selected regions on ANXA1 holds great potential for the development of novel therapeutics treating Heine, A.; Schneiderhan-Marra, N.; inflammatory and cancer diseases.
    [Show full text]